Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/09/22
Avadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022GlobeNewsWire • 10/24/22
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a BetZacks Investment Research • 08/05/22
Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspensionGlobeNewsWire • 07/19/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avadel Pharmaceuticals plc - AVDLNewsfile Corp • 06/15/22
Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2022 Young Investigators Research ForumGlobeNewsWire • 06/03/22
Avadel's stock falls 21% after disclosing new FDA request for experimental narcolepsy drugMarket Watch • 05/26/22
Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/18/22
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential ApprovalBenzinga • 05/11/22
Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/09/22
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9GlobeNewsWire • 05/02/22
Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual MeetingGlobeNewsWire • 04/25/22